Comparison of the Effectiveness of Nerve Hydrodissection With Saline Injection of 5% Dextrose in Carpal Tunnel Syndrome.

NCT07524933 | Active Not Recruiting

• 1 other identifier: 2026528
• Study Type: interventional
• Target: 96
• Locations: 1 country
• Sites: 1

Brief Summary

Comparison of the effectiveness of nerve hydrodissection with saline injection of 5% dextrose in carpal tunnel syndrome.

Conditions

Conditions

Outcome Measures

Primary Outcomes (1)

• Change in pain intensity measured by Visual Analog Scale (VAS)

  The primary outcome is the change in pain intensity assessed by the Visual Analog Scale (VAS, 0-10). The difference between baseline and follow-up scores will be analyzed.

  Baseline to 8 month

Secondary Outcomes (4)

• Change in Qucik DASH score

  Baseline to 8 month

• Change in median nerve cross-sectional area

  Baseline to 8 month

• hange in nerve conduction study parameters

  Baseline to 8 month

• Change in hand grip strength

  Baseline to 8 month

Study Arms (3)

5% dextrose group

ACTIVE COMPARATOR

Ultrasound-guided median nerve hydrodissection with 5% dextrose

Drug: Nerve Hydrodissection with 5% Dextrose

Saline group

SHAM COMPARATOR

Sham ultrasound-guided perineural injection with normal saline

Drug: Nerve Hydrodissection with 5% Dextrose

Splint group

SHAM COMPARATOR

Patients use only a wrist splint without injection therapy

Drug: Nerve Hydrodissection with 5% Dextrose

Interventions

Nerve Hydrodissection with 5% Dextrose DRUG

Injection therapy

Also known as: Saline Injection (Placebo / Sham), Splint group

5% dextrose group; Saline group; Splint group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 18-80 years
• Clinical and electrophysiological diagnosis of mild to moderate carpal tunnel syndrome
• Symptom duration of at least 3 months
• Both male and female participants
• Patients who have not responded adequately to conservative treatment
• Patients who do not wish to undergo surgical treatment
• Ability to provide informed consent

You may not qualify if:

• Severe or very severe carpal tunnel syndrome based on EMG findings
• Previous injection therapy for carpal tunnel syndrome
• Prior wrist or carpal tunnel surgery
• Polyneuropathy or other peripheral neuropathies
• Cervical radiculopathy or proximal median nerve entrapment
• Brachial plexopathy or thoracic outlet syndrome
• Pregnancy
• Malignancy
• Local or systemic infection
• Cognitive impairment affecting cooperation
• Systemic diseases affecting the median nerve (e.g., uncontrolled diabetes mellitus, thyroid disorders)

Sponsors & Collaborators

• Antalya Training and Research Hospital: lead

Study Sites (1)

Antalya Eğitim Araştırma Hastanesi

Antalya, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Disease

Interventions

Glucose; Sodium Chloride; salicylhydroxamic acid

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Hexoses; Monosaccharides; Sugars; Carbohydrates; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 30, 2026
• First Posted: April 13, 2026
• Study Start: January 8, 2026
• Primary Completion (Estimated): July 10, 2026
• Study Completion (Estimated): July 10, 2026
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)